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Galectin-1 (Gal-1) is a member of a highly 
conserved family of animal lectins which binds to the 
common disaccharide [Galβ(1-4)-GlcNAc] on both N- and 
O-glycans decorating cell surface glycoconjugates. Current 
evidence supports a role for Gal-1 in the pathophysiology 
of multiple sclerosis (MS), one of the most prevalent 
chronic inflammatory diseases, as approximately one 
third of MS patients generate high titres of anti-Gal-1 
antibodies. Four different lesion types have been described 
in MS: pattern-1 and -2 lesions are thought to be mediated 
by the autoimmune response, while pattern-3 and -4 
lesions are considered primary oligodendropathy. The 
first two types are experimentally simulated in mice by 
experimental autoimmune encephalomyelitis (EAE), 
while the second two are mimicked by toxic models such 
as cuprizone (CPZ) or lysolecithin (LPC) administration. 
Studies in EAE models have demonstrated that Gal-1 is 
highly expressed in the acute phase of the disease and 
that its deficiency leads to severe inflammation-induced 
neurodegeneration [1]. Regarding its mechanism of action, 
Gal-1 binds to core 2 O-glycans on CD45 and induces 
its retention on the microglial surface, increasing CD45 
phosphatase activity and inhibitory function. Adoptive 
transfer of Gal-1-secreting astrocytes or administration of 
recombinant Gal-1 at disease onset ‒after inflammatory 
cells have entered the CNS‒ attenuates EAE severity 
and reduces microglial activation [1]. However, these 
studies using the EAE model, in which damage is the 
consequence of an immunological attack to myelin, 
have failed in determining whether Gal-1 effects are due 
to damage suppression or response modulation against 
demyelination.
On the other hand, Rinaldi et al. [2] have shown 
that, upon focal LPC-induced demyelination, Gal-
1 treatment induces both a significant decrease in 
demyelinated areas and more efficient remyelination, as 
observed when Gal-1 is administered immediately after or 
4 days after LPC, respectively. This effect is accompanied 
by an attenuated oligodendroglial progenitor, microglial 
and astroglial response, which also reflects lesser myelin 
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Figure 1: Resting microglia are activated toward an M1 phenotype in response to LCP-induced demyelination. Gal-
1 treatment targets these M1-activated microglia, promotes their shift toward an M2-polarized phenotype, thus increasing their myelin 
phagocytic capacity, and leads to oligodendroglial differentiation and remyelination.
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damage. This effect is mediated by Gal-1 targeting 
activated M1 microglia ‒inflammatory and degenerative‒, 
which accelerates the shift toward an M2 phenotype 
‒antiinflammatory and regenerative‒ and increases 
myelin phagocytic capacity, which in turn circumvents 
damage. This switch from M1 to M2 polarization takes 
place 10 days after LPC injection in non-treated animals, 
in agreement with previous studies [3], but as early 
as 3 days after LPC injection in Gal-1-treated ones. 
These Gal-1-induced changes are essential to the onset 
of remyelination, as myelin debris has been proven to 
inhibit oligodendroglial progenitor cell differentiation [4]. 
Previous evidence shows oligodendrocyte differentiation 
to be enhanced in vitro with M2 cell-conditioned media 
and impaired in vivo following intra-lesional M2 cell 
depletion [3]. In agreement with in vivo results, in vitro 
studies show that Gal-1 targets activated microglia, 
promoting an increase in their myelin phagocytic 
capacity and their shift toward an M2 phenotype, and 
leads to oligodendroglial differentiation. However, these 
results also show that a Gal-1-induced shift toward an 
M2 phenotype cannot single-handedly induce factor 
release to enhance oligodendroglial maturation. Instead, 
a direct effect of Gal-1 on oligodendroglial survival 
and/or differentiation appears to be required, together 
with microglial-oligodendrocyte contact enabling the 
phagocytosis of myelin to favor remyelination. Taken 
together, this body of evidence supports the use of Gal-1 
as a potential therapeutic agent for demyelinating diseases 
such as MS [2]. 
Axonal injury occurs early in acute MS lesions. 
Our group has also recently shown that dimeric Gal-1 
prevents neuroregeneration-blocking signals triggered 
by Sema3A binding to the NRP-1/PlexinA4 complex in 
spinal cord injury, which may pave the way for the use 
of this lectin in the treatment of pathologies involving 
neurodegeneration [5]. Rinaldi´s studies further show 
that axonal degeneration and LPC-induced loss of 
contact between axon and myelin sheath are reversed 
by Gal-1 treatment. This neuroprotective effect of Gal-
1 has also been established in studies using electronic 
microscopy, which showed more efficient myelination 
and remyelination in the presence of Gal-1, reflected by 
an increase in the levels of myelin deposition, the number 
of myelinated axons and the number of myelin turns, and 
a decrease in g-ratio and axonal mitochondrial area [2]. 
In vitro studies have identified Sema3A as 
a powerful, selective and reversible inhibitor of 
oligodendroglial precursor cell differentiation, while 
in vivo analyses have shown Sema3A administration 
to induce demyelination and hinder remyelination in 
LPC-treated rats. Moreover, active MS lesions have 
provided evidence of Sema3A expression blocking OLG 
differentiation [6]. In addition, recently published work 
has shown microglial NRP-1 ablation to block microglial 
signaling and antiinflammatory M2 polarization [7]. In 
other words, Gal-1 beneficial effects on remyelination 
could also be thought to involve either the blocking of 
Sema3A binding to NRP-1/PlexinA4 in OLG, or its 
interaction with NRP-1 in microglial cells, which might 
favor a shift toward an M2 phenotype. These hypotheses 
are currently being evaluated by our group.
To sum up, increasing evidence demonstrates 
Gal-1 participation in glial response modulation [1, 2, 
8]. In particular, the T cell-independent LPC-induced 
demyelination model used by Rinaldi et al. [2] makes it 
possible to discriminate the effects of Gal-1 on the glial 
response from its possible effects on damage suppression, 
as damage occurs at the time of LPC injection and is only 
followed by the regenerative process. These findings 
highlight the therapeutic efficacy of Gal-1 in the recovery 
of pattern-3 and -4 lesions, characterized by primary 
oligodendropathy [2]. Altogether, studies so far support 
the use of Gal-1 for the treatment of CNS demyelinating 
diseases such as MS, through microglial modulation, 
polarization and phagocytosis, and remyelination.
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